Prosecution Insights
Last updated: April 19, 2026
Application No. 18/002,636

HAIR CARE COMPOSITION

Non-Final OA §103§112
Filed
Dec 20, 2022
Examiner
WARD, PAUL V
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
CONOPCO, INC.
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
72%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allow Rate
1391 granted / 1672 resolved
+23.2% vs TC avg
Minimal -11% lift
Without
With
+-11.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
36 currently pending
Career history
1708
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
19.1%
-20.9% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
43.7%
+3.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1672 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION STATUS OF THE CLAIMS: Claims 1-21 are pending in this application. Election/Restrictions Applicant’s election of species in the reply filed on October 22, 2025 is acknowledged. All claims were examined in its entirety. Claim Rejections - 35 USC § 112, second paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 9-12 and 18-21 (including claims dependent thereon) are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 9-12 recites the limitation "treatment" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-21 are rejected under 35 U.S.C. 103 as being unpatentable over Chang et al., (US Pub. 20190328647). Applicant claims the following: PNG media_image1.png 106 644 media_image1.png Greyscale Additionally, in claim 13, Applicant claims a method for treating dandruff with said hair composition, and in dependent claims 2-12 and 14-21, Applicant claims the hair composition with various weight ration of homopolymer/copolymer to piroctone and various piroctone, copolymers and their different weight ratio. Chang teaches hair compositions comprising a piroctone compound, cationic homopolymer/and/or copolymer comprising an acrylamidopropyltrimonium moiety having a charge density of 0.25-7 and molecular weight of 250,000- 2,500,000 (at pH 7). Additionally, this reference teaches that the hair compositions can be used as anti-dandruff agents. (See Abstract and paragraphs [0025], [0101]-[0102] and [0104]). Chang does not teach hair compositions comprising a piroctone compound, cationic homopolymer/and/or copolymer comprising an acrylamidopropyltrimonium moiety having a charge density of 3.5 meq/g and molecular weight of 100,000-500,000 g/mol. It would have been obvious to one having ordinary skill in the art at the time of the invention to be motivated to apply the method of Chang by including a hair composition comprising a piroctone compound, cationic homopolymer/and/or copolymer comprising an acrylamidopropyltrimonium moiety having a charge density of 3.5 meq/g and molecular weight of 100,000-500,000 g/mol for the purpose of maximizing the efficacy and effects, and thus treating dandruff. The ranges of the amounts of the ingredients of a composition amount to matters which could be optimized by a person skill in the art through repeated experimentation, and the effect could be achieve and predicted by repeated or routine experimentation. Thus, one having ordinary skill in the art at the time of the invention wanting a new hair composition to treat dandruff would be motivated to apply the method of Chang by altering the MW and charge density. The ranges of the amounts of constituent ingredients of a composition amount to matters which could be optimized by a person skilled in the art through repeated or routine experimentation, and the effects achieved could be predicted. Thus, Applicant’s claims are obvious in view of the teachings of Chang. Since Applicant’s claims are prima facie obvious in view of the teachings of Chang, Applicant’s claims are obvious, and therefore, rejected under 35 U.S.C. 103. Conclusion Claims 1-21 are pending. Claims 1-21 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL V WARD/ Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Dec 20, 2022
Application Filed
Sep 11, 2025
Examiner Interview Summary
Sep 11, 2025
Applicant Interview (Telephonic)
Oct 17, 2025
Examiner Interview Summary
Oct 17, 2025
Applicant Interview (Telephonic)
Feb 02, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599666
PHOTOLYTIC COMPOUNDS AND TRIPLET-TRIPLET ANNIHILATION MEDIATED PHOTOLYSIS
2y 5m to grant Granted Apr 14, 2026
Patent 12600705
HEAT SHOCK PROTEIN MODULATORS AND ANTI-HUNTINGTON DISEASE THERAPEUTIC AGENTS
2y 5m to grant Granted Apr 14, 2026
Patent 12600703
METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES
2y 5m to grant Granted Apr 14, 2026
Patent 12600700
IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY
2y 5m to grant Granted Apr 14, 2026
Patent 12599606
THERAPIES WITH 3RD GENERATION EGFR TYROSINE KINASE INHIBITORS
2y 5m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
72%
With Interview (-11.0%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 1672 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month